Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neuropilin-1 receptor antagonists - Trizell

Drug Profile

Research programme: neuropilin-1 receptor antagonists - Trizell

Alternative Names: EG0048; EG012; EG012-014; EG01257; EG014; EG3287

Latest Information Update: 23 Nov 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ark Therapeutics
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Neuropilin-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 08 Nov 2012 Discontinued - Preclinical for Solid tumours in United Kingdom (unspecified route)
  • 22 May 2012 Preclinical development is ongoing in United Kingdom
  • 11 Mar 2011 The neuropilin-1 receptor antagonists programme is available for licensing \www.arktherapeutics.com\
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top